Malvern, United States
Ocugen, founded in 2013 and headquartered in the United States, is a biotechnology company dedicated to tackling major blindness diseases with innovative gene therapies. Through their unique modifier gene therapy platform, Ocugen aims to address the significant unmet needs of large patient populations using a gene-agnostic approach. This strategic direction positions the company at the forefront of potential breakthroughs within the biotechnology field.
Their guiding philosophy, reflected in their slogan, "Approaching healthcare innovation with purpose and agility to deliver new breakthroughs for people facing disease," underscores their commitment to impacting patients' lives globally. The company's agile approach and robust intellectual capital set a strong foundation for continued innovation and potential market leadership.
Their credibility is further enhanced by their latest Post IPO Equity investment from Janus Henderson Investors on 01 December 2025. This financial backing highlights investor confidence in Ocugen's promising trajectory and potential for substantial returns.
